companydata.dkcompanydata.dk

Hoba Therapeutics ApS: Financial statements 2026

CVR: 38231170

Source: annual report 2026, Danish Business Authority

01/04/2025 – 31/03/2026

Hoba Therapeutics ApS (CVR 38231170) has filed annual accounts for 2026. In 2026, the company reported a gross profit of DKK -61,710,701 and a net result of DKK -67,693,868 compared with DKK -43,008,287 the year before. Equity in the 2026 report amounted to DKK 1,143,899. The solvency ratio was 7.3%. The company had 7 employees in the financial year.

Gross Profit
DKK -61,710,701
Profit/Loss
DKK -67,693,868
Equity
DKK 1,143,899
Total Assets
DKK 15,583,219
Employees
7

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2026--61.7M-67.7M1.1M7
2025--38.3M-43M26.1M8
2024--20.9M-27.8M69.1M8
2023--9.4M-13.9M-32.9M6
20220-7.2M-10.9M-19M3

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like Hoba Therapeutics ApS

Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.

Try the lead list generator

Events in 2026

Hoba Therapeutics ApS updates contact informationOct 8, 2026

Contact info changed: new email: [email protected], new website: www.hobatherapeutics.com (October 8, 2026).

Hoba Therapeutics ApS updates contact informationJun 3, 2026

Contact info changed: new email: [email protected], new website: www.hobatherapeutics.com (June 3, 2026).

Gonçalo Nuno Nunes da Silva Rebelo de Andrade joins the board of Hoba Therapeutics ApSJun 1, 2026

As of June 1, 2026, Gonçalo Nuno Nunes da Silva Rebelo de Andrade has joined the board of directors of Hoba Therapeutics ApS.

Gonçalo Nuno Nunes da Silva Rebelo de Andrade leaves the board of Hoba Therapeutics ApSMay 31, 2026

As of May 31, 2026, Gonçalo Nuno Nunes da Silva Rebelo de Andrade has left the board of directors of Hoba Therapeutics ApS.

Jean Marcel André Combalbert leaves the board of Hoba Therapeutics ApSMay 31, 2026

As of May 31, 2026, Jean Marcel André Combalbert has left the board of directors of Hoba Therapeutics ApS.

Hoba Therapeutics ApS changes addressMay 13, 2026

Address changed to Nordre Fasanvej 215, 2000 Frederiksberg (May 13, 2026).

Hoba Therapeutics ApS updates contact informationMay 13, 2026

Contact info changed: new email: [email protected], new website: www.hobatherapeutics.com (May 13, 2026).

Hoba Therapeutics ApS updates contact informationApr 14, 2026

Contact info changed: new email: [email protected], new website: www.hobatherapeutics.com (April 14, 2026).

Camilla Petrycer Hansen leaves the board of Hoba Therapeutics ApSApr 8, 2026

As of April 8, 2026, Camilla Petrycer Hansen has left the board of directors of Hoba Therapeutics ApS.

Kuang He leaves the board of Hoba Therapeutics ApSApr 8, 2026

As of April 8, 2026, Kuang He has left the board of directors of Hoba Therapeutics ApS.

About Hoba Therapeutics ApS

Hoba Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Gonçalo Nuno Nunes da Silva Rebelo de Andrade. The board consists of Gonçalo Nuno Nunes da Silva Rebelo de Andrade (chair) and Gunnar Magnus Severus Modée Persson. The company's owners include Novo Holdings A/S, Danmarks Eksport- og Investeringsfond and EIC Fund. The company has 2 employees (2026). In 2026, the company reported a gross profit of DKK -61,710,701 and a net result of DKK -67,693,868 compared with DKK -43,008,287 the year before. Equity in the 2026 report amounted to DKK 1,143,899.

Source: annual report 2026, Danish Business Authority